This has made PARP‐1 a target of interest in cancer therapeutics, and the discovery of small molecule inhibitors of PARP‐1 has recently resulted in the approval of ‘parib’ drugs such as olaparib, rucaparib, veliparib, and talazoparib for different stages of breast and ovarian cancers. Here, PARP1 is linked to ovarian cancer.